{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:58Z","timestamp":1786979938320,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fundaci\u00f3n Te\u00f3filo Hernando"},{"name":"Incyte International Sarl, Morges, Switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06806-7","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:28:47Z","timestamp":1768886927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["One-year consolidation with Ponatinib 15\u00a0mg in chronic myeloid leukaemia on deep molecular response with Imatinib"],"prefix":"10.1007","volume":"105","author":[{"given":"Luc\u00eda","family":"P\u00e9rez-Lamas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Manzanares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Hern\u00e1ndez Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Felipe","family":"Casado Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"G\u00f3mez Casares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Xicoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Ferrer Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Ort\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"De Paz Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Osorio Prendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Perez Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Ruiz Nu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jimenez Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Boqu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sierra Pacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Martinez Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Carre\u00f1o-Tarragona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayte","family":"Coiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Garcia-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"6806_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F et al (2017) Long-Term outcomes of Imatinib treatment for chronic myeloid leukemia. N Engl J Med 376:917\u2013927. https:\/\/doi.org\/10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"6806_CR2","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ et al (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than Imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107:4532\u20134539. https:\/\/doi.org\/10.1182\/blood-2005-07-2947","journal-title":"Blood"},{"key":"6806_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-018-0125-0","volume":"8","author":"JC Hern\u00e1ndez-Boluda","year":"2018","unstructured":"Hern\u00e1ndez-Boluda JC, Pereira A, Pastor-Gal\u00e1n I et al (2018) Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. Blood Cancer J 8:91. https:\/\/doi.org\/10.1038\/s41408-018-0125-0","journal-title":"Blood Cancer J"},{"key":"6806_CR4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D et al (2017) Long-Term Follow-Up of the French stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 35:298\u2013305. https:\/\/doi.org\/10.1200\/JCO.2016.68.2914","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6806_CR5","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M et al (2017) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 129:846\u2013854. https:\/\/doi.org\/10.1182\/blood-2016-09-742205","journal-title":"Blood"},{"key":"6806_CR6","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ et al (2017) Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the enestfreedom study. Leukemia 31:1525\u20131531. https:\/\/doi.org\/10.1038\/leu.2017.63","journal-title":"Leukemia"},{"key":"6806_CR7","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M et al (2015) Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2:e528\u2013535. https:\/\/doi.org\/10.1016\/S2352-3026(15)00196-9","journal-title":"Lancet Haematol"},{"key":"6806_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747\u2013757. https:\/\/doi.org\/10.1016\/S1470-2045(18)30192-X","journal-title":"Lancet Oncol"},{"key":"6806_CR9","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO.23.01647","volume":"42","author":"F-X Mahon","year":"2024","unstructured":"Mahon F-X, Pfirrmann M, Dulucq S et al (2024) European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for Treatment-Free remission. J Clin Oncol Off J Am Soc Clin Oncol 42:1875\u20131880. https:\/\/doi.org\/10.1200\/JCO.23.01647","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6806_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P et al (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped Imatinib after durable undetectable disease. J Clin Oncol Off J Am Soc Clin Oncol 32:424\u2013430. https:\/\/doi.org\/10.1200\/JCO.2012.48.5797","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6806_CR11","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ajh.26550","volume":"97","author":"FG Haddad","year":"2022","unstructured":"Haddad FG, Sasaki K, Issa GC et al (2022) Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol 97:856\u2013864. https:\/\/doi.org\/10.1002\/ajh.26550","journal-title":"Am J Hematol"},{"key":"6806_CR12","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J et al (2013) A phase 2 trial of Ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783\u20131796. https:\/\/doi.org\/10.1056\/NEJMoa1306494","journal-title":"N Engl J Med"},{"key":"6806_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A et al (2016) Ponatinib versus Imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol 17:612\u2013621. https:\/\/doi.org\/10.1016\/S1470-2045(16)00080-2","journal-title":"Lancet Oncol"},{"key":"6806_CR14","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"J Cortes","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E et al (2021) Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood 138:2042\u20132050. https:\/\/doi.org\/10.1182\/blood.2021012082","journal-title":"Blood"},{"key":"6806_CR15","doi-asserted-by":"publisher","first-page":"1426974","DOI":"10.3389\/fphar.2024.1426974","volume":"15","author":"M Manzanares","year":"2024","unstructured":"Manzanares M, Ramos-Mart\u00edn F, Rodr\u00edguez-Mora S et al (2024) Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with Ponatinib. Front Pharmacol 15:1426974. https:\/\/doi.org\/10.3389\/fphar.2024.1426974","journal-title":"Front Pharmacol"},{"key":"6806_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41571-020-0367-1","volume":"17","author":"DM Ross","year":"2020","unstructured":"Ross DM, Hughes TP (2020) Treatment-free remission in patients with chronic myeloid leukaemia. Nat Rev Clin Oncol 17:493\u2013503. https:\/\/doi.org\/10.1038\/s41571-020-0367-1","journal-title":"Nat Rev Clin Oncol"},{"key":"6806_CR17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon F-X, R\u00e9a D, Guilhot J et al (2010) Discontinuation of Imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035. https:\/\/doi.org\/10.1016\/S1470-2045(10)70233-3","journal-title":"Lancet Oncol"},{"key":"6806_CR18","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1038\/s41375-018-0264-0","volume":"32","author":"DM Ross","year":"2018","unstructured":"Ross DM, Pagani IS, Shanmuganathan N et al (2018) Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia 32:2572\u20132579. https:\/\/doi.org\/10.1038\/s41375-018-0264-0","journal-title":"Leukemia"},{"key":"6806_CR19","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/ajh.24120","volume":"90","author":"S Mori","year":"2015","unstructured":"Mori S, Vagge E, le Coutre P et al (2015) Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol 90:910\u2013914. https:\/\/doi.org\/10.1002\/ajh.24120","journal-title":"Am J Hematol"},{"key":"6806_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3324\/haematol.2015.139899","volume":"101","author":"S-E Lee","year":"2016","unstructured":"Lee S-E, Choi SY, Song H-Y et al (2016) Imatinib withdrawal syndrome and longer duration of Imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 101:717\u2013723. https:\/\/doi.org\/10.3324\/haematol.2015.139899","journal-title":"Haematologica"},{"key":"6806_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","volume":"18","author":"M Okada","year":"2018","unstructured":"Okada M, Imagawa J, Tanaka H et al (2018) Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a Second-line treatment. Clin Lymphoma Myeloma Leuk 18:353\u2013360e1. https:\/\/doi.org\/10.1016\/j.clml.2018.03.004","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6806_CR22","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","volume":"7","author":"S Kimura","year":"2020","unstructured":"Kimura S, Imagawa J, Murai K et al (2020) Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol 7:e218\u2013e225. https:\/\/doi.org\/10.1016\/S2352-3026(19)30235-2","journal-title":"Lancet Haematol"},{"key":"6806_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","volume":"61","author":"NP Shah","year":"2020","unstructured":"Shah NP, Garc\u00eda-Guti\u00e9rrez V, Jim\u00e9nez-Velasco A et al (2020) Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma 61:650\u2013659. https:\/\/doi.org\/10.1080\/10428194.2019.1675879","journal-title":"Leuk Lymphoma"},{"key":"6806_CR24","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","volume":"35","author":"JP Radich","year":"2021","unstructured":"Radich JP, Hochhaus A, Masszi T et al (2021) Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the enestfreedom trial. Leukemia 35:1344\u20131355. https:\/\/doi.org\/10.1038\/s41375-021-01205-5","journal-title":"Leukemia"},{"key":"6806_CR25","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-021-01260-y","volume":"35","author":"TP Hughes","year":"2021","unstructured":"Hughes TP, Clementino NCD, Fominykh M et al (2021) Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: enestop 5-year update. Leukemia 35:1631\u20131642. https:\/\/doi.org\/10.1038\/s41375-021-01260-y","journal-title":"Leukemia"},{"key":"6806_CR26","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M et al (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 103:2794\u20132799. https:\/\/doi.org\/10.1073\/pnas.0510423103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6806_CR27","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1182\/blood.V130.Suppl_1.1624.1624","volume":"130","author":"V Garc\u00eda Guti\u00e9rrez","year":"2017","unstructured":"Garc\u00eda Guti\u00e9rrez V, Novo A, Jimenez-Velasco A et al (2017) A Conservative tailoring of Ponatinib dose in chronic myeloid leukemia patients can diminish adverse events while maintaining efficacy. Blood 130:1624. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.1624.1624","journal-title":"Blood"},{"key":"6806_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J et al (2018) Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132:393\u2013404. https:\/\/doi.org\/10.1182\/blood-2016-09-739086","journal-title":"Blood"},{"key":"6806_CR29","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.1182\/blood-2018-99-117075","volume":"132","author":"M Alfayez","year":"2018","unstructured":"Alfayez M, Kantarjian HM, Kadia TM et al (2018) Ponatinib and bosutinib discontinuation in chronic myeloid leukemia (CML): single center experience. Blood 132:5447. https:\/\/doi.org\/10.1182\/blood-2018-99-117075","journal-title":"Blood"},{"issue":"24","key":"6806_CR30","doi-asserted-by":"publisher","first-page":"02403","DOI":"10.1016\/j.clml.2024.11.003","volume":"2152\u20132650","author":"FG Haddad","year":"2024","unstructured":"Haddad FG, Sasaki K, Senapati J et al (2024) Successful Treatment-Free remission after Ponatinib discontinuation in pretreated patients with chronic myeloid leukemia in chronic phase. Clin Lymphoma Myeloma Leuk S 2152\u20132650(24):02403\u201302400. https:\/\/doi.org\/10.1016\/j.clml.2024.11.003","journal-title":"Clin Lymphoma Myeloma Leuk S"},{"key":"6806_CR31","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF et al (2019) De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol 6:e375\u2013e383. https:\/\/doi.org\/10.1016\/S2352-3026(19)30094-8","journal-title":"Lancet Haematol"},{"key":"6806_CR32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bjh.17286","volume":"193","author":"S Claudiani","year":"2021","unstructured":"Claudiani S, Apperley JF, Szydlo R et al (2021) TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. Br J Haematol 193:346\u2013355. https:\/\/doi.org\/10.1111\/bjh.17286","journal-title":"Br J Haematol"},{"key":"6806_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2141.2010.08453.x","volume":"153","author":"E Bachy","year":"2011","unstructured":"Bachy E, Bernaud J, Roy P et al (2011) Quantitative and functional analyses of CD4(+) CD25(+) FoxP3(+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on Imatinib mesylate. Br J Haematol 153:139\u2013143. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08453.x","journal-title":"Br J Haematol"},{"key":"6806_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1365-2141.2011.08939.x","volume":"157","author":"K Ohyashiki","year":"2012","unstructured":"Ohyashiki K, Katagiri S, Tauchi T et al (2012) Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of Imatinib. Br J Haematol 157:254\u2013256. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08939.x","journal-title":"Br J Haematol"},{"key":"6806_CR35","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","volume":"102","author":"D Rea","year":"2017","unstructured":"Rea D, Henry G, Khaznadar Z et al (2017) Natural killer-cell counts are associated with molecular relapse-free survival after Imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica 102:1368\u20131377. https:\/\/doi.org\/10.3324\/haematol.2017.165001","journal-title":"Haematologica"},{"key":"6806_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/jcm10010042","volume":"10","author":"L Vig\u00f3n","year":"2020","unstructured":"Vig\u00f3n L, Luna A, Gal\u00e1n M et al (2020) Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on Treatment-Free remission. J Clin Med 10:42. https:\/\/doi.org\/10.3390\/jcm10010042","journal-title":"J Clin Med"},{"key":"6806_CR37","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3389\/fphar.2019.01232","volume":"10","author":"N Climent","year":"2019","unstructured":"Climent N, Plana M (2019) Immunomodulatory activity of tyrosine kinase inhibitors to elicit cytotoxicity against cancer and viral infection. Front Pharmacol 10:1232. https:\/\/doi.org\/10.3389\/fphar.2019.01232","journal-title":"Front Pharmacol"},{"key":"6806_CR38","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/leu.2012.348","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Auvinen K, Kreutzman A et al (2013) Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 27:914\u2013924. https:\/\/doi.org\/10.1038\/leu.2012.348","journal-title":"Leukemia"},{"key":"6806_CR39","doi-asserted-by":"publisher","first-page":"769730","DOI":"10.3389\/fonc.2021.769730","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zou J, Cheng F, Li W (2021) Treatment-Free remission in chronic myeloid leukemia and new approaches by targeting leukemia stem cells. Front Oncol 11:769730. https:\/\/doi.org\/10.3389\/fonc.2021.769730","journal-title":"Front Oncol"},{"key":"6806_CR40","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","volume":"116","author":"A Kreutzman","year":"2010","unstructured":"Kreutzman A, Juvonen V, Kairisto V et al (2010) Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116:772\u2013782. https:\/\/doi.org\/10.1182\/blood-2009-12-256800","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06806-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06806-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06806-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:03:50Z","timestamp":1771398230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06806-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6806"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06806-7","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Valent\u00edn Garc\u00eda-Guti\u00e9rrez has received consulting fees from BMS, Incyte, Novartis and Pfizer; travel support from BMS, Incyte, Novartis and Pfizer; institutional research grant from Incyte, BMS, GSK and Novartis; and honoraria from BMS, Incyte, GSK, Novartis, and PfizerBlanca Xicoy: grant and honoraria from IncyteJoaquin Martinez: grant from Incyte, honoraria from Novartis, Ascentagene and IncityFrancisca Ferrer: grant from Incyte, honoraria from NovartisGuillermo Ort\u00ed has received consulting fees from BMS, Incyte, Novartis and Pfizer; travel support from BMS, Incyte, Novartis and Pfizer; institutional research grant from Incyte; and honoraria from BMS, Incyte, Jazz, Novartis, Pfizer, Sanofi and TherakosMagdalena Sierra: grant from Novartis, travel support from Pfizer, Novartis and IncyteMaria Teresa G\u00f3mez Casares:has received consulting fees from BMS, Incyte, Novartis and Pfizer; travel support from BMS, Incyte, Novartis and Pfizer; institutional research grant from IncyteLuis Felipe Casado Montero: grant and honoraria from Novartis, Pfizer, BMS and IncyteRaul Perez Lopez: grant and honoraria from IncyteRaquel de Paz: Honoraria from IncyteJuan Carlos Hern\u00e1ndez Boluda: Travel grant and advisory board honoraria from Incyte.The remaining co-authors have no competing interests","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}